Hervolution Therapeutics Appoints Biotech Builder J. Robert Coleman As CEO To Accelerate Groundbreaking Immunotherapies To Treat Dark Genome Targets In Cancer, Aging, and Neurodegeneration
Hervolution Therapeutics Appoints Biotech Builder J. Robert Coleman As CEO To Accelerate Groundbreaking Immunotherapies To Treat Dark Genome Targets In Cancer, Aging, and Neurodegeneration
12/19/23, 1:20 PM
Location
copenhagenIndustry
biotechnology
Position
chairman
chief executive officer
HERVOLUTION Therapeutics ApS , a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer.
Company Info
Location
copenhagen, capital region of denmark, denmark
Additional Info
HERVolution Therapeutics (formerly InProTher Aps) is a dark genome-focused biotechnology company based in Copenhagen, Denmark, and the U.S., pioneering novel human endogenous retrovirus (HERV)-targeted immunotherapies to address diseases of aging. With its proprietary engineering approaches, HERVolution has rationally redesigned HERV-antigens to yield a new class of highly immunogenic antigens to address cancer, metabolic, and other aging-related diseases. The company's world-class scientific team has advanced a strong product development pipeline, with lead program, IPT-001, anticipated to enter the clinic in 2025.